Exploring Potential HER2-Positive Breast Cancer Treatments for the Future
Jasmeet C. Singh, MD, discusses the future of the treatment landscape for HER2-positive breast cancer following positive new research presented at the 2019 San Antonio Breast Cancer Symposium.
Jasmeet C. Singh, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of the treatment landscape for HER2-positive breast cancer following positive new research presented at the 2019 San Antonio Breast Cancer Symposium (SABCS).
Although the field has come a long with developing new treatment options for patients with breast cancers that overexpress HER2, Singh notes that there is still room for improvement. One possibility for the future is that novel agents will be used to develop promising combinations to further improve pathologic complete response (pCR) rates and overall response rates.
There have been exciting pCR data in triple-negative disease showing that the addition of immunotherapy improves pCRs. Singh says it may also be possible to study how surgery can be avoided in some patients with HER2-positive disease.
Learn more about the presentation from 2019 SABCS:https://www.targetedonc.com/conference/sabcs-2019
<< View more resources and information regarding breast cancer
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Real-World Data and AI Help Improve ILD Management in HER2+ Breast Cancer
December 13th 2024Project EVOLVE findings show how AI-driven real-world data analysis, combined with targeted educational interventions, can enhance adverse event monitoring and improve patient outcomes for those with HER2+ breast cancer.
Read More
